Welcome to our dedicated page for TC BIOPHARM HOLDINGS PLC SEC filings (Ticker: TCBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for TC BioPharm (Holdings) PLC Warrants (TCBPW) provides access to regulatory documents related to the warrant class and its issuer, TC BioPharm (Holdings) PLC. As a foreign private issuer, TC BioPharm files reports under Form 20-F and furnishes current information on Form 6-K, which can include updates on shareholder meetings, capital structure changes and other material events that may be relevant to holders of warrants and other securities.
A notable filing for this security class is a Form 25 (25-NSE), which is a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934. In this filing, Nasdaq Stock Market LLC certifies that it has complied with its rules to strike the American Depositary Shares, Warrant class of securities of TC BioPharm (Holdings) PLC from listing and/or withdraw registration on the exchange. This document is important for understanding the listing status of TCBPW on Nasdaq.
Another example of relevant disclosure is a Form 6-K reporting the results of TC BioPharm’s 2025 Annual General Meeting. That report details resolutions passed by shareholders, including receipt of the annual report and audited financial statements, approval of the directors’ remuneration report, re-appointment of the U.K. statutory auditor, authorization of the audit committee to determine auditor remuneration, share subdivision and reclassification, authority to allot shares, disapplication of pre-emption rights, amendments to the Articles of Association to create B Deferred Shares, and authorization for off-market purchases of B Deferred Shares. These items relate to the company’s governance and capital structure, which can affect securities linked to its equity.
On Stock Titan, investors can use AI-powered tools to review filings such as Form 6-K and Form 25, with summaries that explain key points in plain language. Real-time updates from EDGAR help users see new filings as they appear, while structured access to documents allows focused review of topics like listing status, share capital changes and shareholder approvals that may be relevant to the historical and regulatory context of TCBPW.
TC BioPharm (Holdings) plc reported the results of its 2025 Annual General Meeting held on August 29, 2025, where all resolutions were passed on a poll. Shareholders received the company’s annual report and audited financial statements for the year ended December 31, 2024 and approved the Directors’ Remuneration Report for that year. Ecovis Wingrave Yeats was re-appointed as U.K. statutory auditor, and the Audit Committee was authorized to set the auditor’s remuneration for the year ending December 31, 2025.
Shareholders approved a subdivision of each ordinary share of £0.0001 into 1 ordinary share of £0.000001 and 1 B deferred share of £0.000099, and adopted detailed Articles defining B deferred shares as having no dividend, voting, or general meeting rights and only minimal economic rights. The directors were authorized under U.K. law to allot shares or rights up to an aggregate nominal amount of £200,000,000 for five years and to disapply pre-emption rights on such allotments for the same period. The company was also authorized, subject to the new Articles, to make off-market purchases and cancellations of its B deferred shares for up to five years.
What happened: Nasdaq has filed a Form 25 to remove a class of TC BioPharm (Holdings) plc securities from Nasdaq listing and/or registration.
Who and when: The filing names the issuer as TC BioPharm (Holdings) plc and is signed by a Nasdaq hearings advisor on 2025-08-08. The affected classes are the American Depositary Shares and Warrants.
FAQ
What is the current stock price of TC BIOPHARM HOLDINGS PLC (TCBPW)?
